AbstractöObjective: To determine whether a formula containing n76 and n73 long-chain polyunsaturated fatty acids (LCP) from puri¢ed phospholipids increases the content of 20:4n76 and 22:6n73 of plasma lipids and modi¢es the plasma antioxidant capacity in low-birth-weight infants. Study design: Seventeen infants were fed a conventional formula for low birth-weight infants (F), and 17 a formula containing n76 and n73 LCP from puri¢ed pig-brain phospholipids (LCP-F). Fourteen infants receiving human milk from a human milk bank were used as a reference (HM). Growth index were measured and blood samples were taken at entry and after 15 days and 30 days of feeding.
Introduction
Studies with animals have shown an association between very low levels of 22:6n73 in the retina and central nervous system and measures of visual and behavioural outcomes (1, 2) . These reports and the observation that infants fed conventional formula have lower erythrocyte and plasma levels of the n76 and n76 LCP led to the consideration that infants may benefit from dietary supplementation with 22:6n73 or both 20:4n76 and 22:6n73. The ratio of the precursors, linoleic and linolenic acids in formulas influences LCP content in tissues. However, varying the amounts and ratios of essential fatty acids did not increase LCP levels in plasma and erythrocytes to those found in breast-fed infants (3) .
It has been shown that infants fed formulas containing 22:6n73 or both 22:6n73 and 20:4n76 have higher levels of the added LCP in plasma and red cells than infants fed formulas without LCP (4) . However, whether infants may benefit from a preformed dietary source of LCP for maturation of visual or mental system remains controversial. Several clinical trials have shown functional advantages of LCP supplementation for preterm infants (5) (6) (7) (8) (9) (10) (11) , although some of the effects found were transient (8, 11) . Preterm infants fed formulas supplemented with 22:6n73 had a increase in visual acuity (8) (9) (10) (11) , and better retinal responses to light (5, 6) . Studies of the visual system in term infants have shown contradictory results and are less conclusive (11) (12) (13) (14) (15) .
Some concerns have been raised about dietary n73 LCP supplementation and infant growth (16) . Studies done in preterm infants using formulas with 22:6n73 but no 20:4n76, found increased plasma and erythrocyte levels of 22:6n73 and 20:5n73 but reduced levels of 20:4n76 (5, 8) . This fact has been related to slower growth rate (17, 18) , and also to inconsistent developmental results in preterm infants (19) . Using formulas supplemented with low 20:5n73 fish oils, less marked, but statistically significant differences on growth were reported between infants fed the supplemented and the unsupplemented formula (11) . Other studies using both n73 and n76 supplemented formulas did not report any differences in growth (20) (21) (22) .
Sources of LCP that have been studied as possible additives to infant formulas are fish oil, egg lipids and fungal-and algal-derived oils. Fish oils contain 22:6n73 and varying amounts of 20:5n73, depending on the species. The main LCP in algal oils is 22:6n73 and in fungal oils is 20:4n76. Egg lipids or phospholipids contain both 22:6n73 and 20:4n76.
Studies evaluating the postnatal LCP status in infants may be classified into two categories: those focusing on plasma and tissue responses of infants fed different sources of LCP and those mainly focusing on the physiological effects of these fatty acids (visual function and central-nervous-system development). In the present study an alternate LCP source (purified brain phospholipids) was evaluated in low-birth-weight infants from a compositional point of view.
LCP addition to current infant formulas may increase antioxidant requirements in the infants. Some studies specifically assessed parameters related to the oxidative stability of the LCP in plasma of infant fed LCP supplemented formulas (23) (24) (25) (26) . Our study also reports the total antioxidant capacity of plasma as an indirect measurement of the risk of peroxidation.
Methods

Study population and design
Preterm infants, who were born at the Porto Alegre Clinic Hospital (University of Rio Grande Do Sul, Brazil), were initially included in the study. They were medically stable, without major respiratory or metabolic illness or severe congenital deformities. The project was approved by the Hospital's Ethics Committee and written informed consent was obtained from all parents. Gestational age and estimation of weight according to gestational age was done by standard methods (27, 28) . Infants who did not fulfil the study requirements and those who suffered any illness that impaired enteral feeding were excluded from the study.
One group of infants received human milk from a human milk bank (HM), another group a conventional formula for low birth-weight infants (F) and the last group the same formula manufactured to contain LCP from the n76 and n73 series (LCP-F). Infants in the human7milk group received a protein and mineral supplement (1.5 g/5 kcal) containing lactoalbumin (38.52 g/100 g), maltodextrin (36.78 g/100 g) calcium caseinate (19.23 g/100 g) and calcium hydrogen phosphate (5.58 g/100 g). By the day 10 of life, all infants received a vitamin supplement (Trivisol 1 , BristolMayer). If the haemoglobin level was lower than 7 g/ dl, a 60% red-blood-cell concentrate was administered 10 ml per kg of body weight.
Infants were studied from when they started enteral feeding to 1 month later. Tolerance, quantity of ingested food and body weight were monitored daily. Other anthropometric measurements, such as length and head circumference, were recorded weekly. Blood samples were taken at entry and after 15 days and 30 days of feeding.
The LCP supplemented-formula was prepared to contain about 0.3% and 0.2% of total fatty acids as 20:4n76 and 22:6n73 respectively (Table 1) . This formulation was made by incorporation of a highly purified phospholipid source from pig brains obtained as previously described (29) and stabilised with 250 mg a-tocopherol and 750 mg ascorbyl palmitate per kg of phospholipids. Part of the fat in the control diet (8.3%) was replaced by the purified phospholipids, and an additional 30.8 mg ascorbyl palmitate and 15.4 mg a-tocopherol were added per kg of formula. The final product showed good stability under storage conditions (30) . No adverse effects were observed when this formula was fed to newborn pigs (31, 32). All milk formulas were prepared by the Research and Development Department of PULEVA currently Abbott Laboratories S.A., Granada, Spain.
Lipid analysis
Plasma was separated by centrifugation and stored at 7208C until analysis. An aliquot of plasma (0.1 ml) was added with pentadecanoic acid (20 mg) as internal standard and methylated (33) . Fatty-acid composition of human milk was obtained by methylation of 16 samples (0.1 ml) from the human milk bank as previously described (34) . The fatty-acid composition of the main lipid fractions in plasma was also determined. Lipids were extracted from plasma, then separated by TLC (31) and converted to methyl esters as above (33) .
Fatty-acid methyl esters from total plasma lipids and their fractions were separated and quantified by gas liquid chromatography, using a Hewlett Packard no. 5890 gas chromatograph (Hewlett Packard Co., Palo Alto, CA) equipped with a flame ionisation detector and a 60 m long60.32 mm internal diameter capillary SP-2330 column (Supelco, Bellefonte, PA). Peaks were identified by comparison with known standards (Sigma, Sant Louis, MO) and the results were reported as concentrations (mg/ dl) or normalized percentages of area.
Measurement of plasma antioxidant capacity
Plasma antioxidant capacity (PAC) was determined as the capacity of plasma to inhibit the oxidation of a highly-susceptible-substrate to lipid peroxidation (a pig brain homogenate in a 150 mM buffer TRIS, pH 7.4). This method was based on that described by Can˜as et al (35) . The control reaction consisted of an aliquot of the brain homogenate containing 1.5 mg of protein, and TRIS buffer to complete a final volume of 0.5 ml. To prepare each sample reaction 50 ml of the TRIS buffer volume in the control reaction were substituted by 50 ml of plasma. Lipid peroxidation was induced by incubating control and sample reactions per duplicate at 378C in a shaker water bath, and was assessed by the TBARS formation at 30 min of incubation. The production of TBARS was determined according to Buege and Aust (36) . PAC was expressed as the percentage of inhibition of the peroxidation in the control reaction.
Data analysis
Unbalanced repeated measures ANOVA was used to assess the effects of diet and age and their interaction on fatty acid composition of plasma lipids and fractions, and on growth parameters (PC-90) version of 5V BMDP programme, BMDP Statistical Software, Inc., Los Angeles, CA). When a significant effect was found for diet, time and time6diet, multiple Bonferroni comparisons were done. Anthropometric parameters at birth and PAC at each time point were compared by one-way ANOVA. No sample size and power calculation was performed at the out set of the study.
Results
Sixty infants were initially enrolled in the study. Twelve of them were withdrawn early (20% drop-out) because of poor compliance with the study procedures, unavailability of human milk in the milk bank, or occurrence of any illness that compromised the study participation.
Gestational age, body weight, length, and head circumference on the infants that dropped-out of the study by groups were: 31.1+4. (30) (31) (32) (33) (34) (35) for HM, F and LCP-F, respectively. The two formulas were well tolerated and no other potentially adverse effect associated with feeding was noted. Enteral feeding started on average at 2.9 days of age (median 2, range 1-5) for the F group, at 2.9 days (median 2, range 1-5) for the LCP-F group and 3.5 days (median 3.5, range 1-7) for the HM group. Enteral feeding of 120 kcal/kg/day was attained on average at 10.2 days (median 10, range 6-16) for the F group, at 9.6 days (median 9, range 5-14) and at 10.1 days (median 10, range 5-15) for the HM group.
The fatty acid composition of total plasma lipids is given in Table 3 . The measurements of plasma fatty acid composition were done in 37 infants from the 48 studied, 8 in the HM group, 15 in the F group and 14 Regarding the LCP composition of total plasma lipids, the time-course of 20:4n76 was different for the three feeding groups: in HM group, 20:4n76 content increased by nearly 2 mg/dl with time, whereas a sharp decrease was found for this fatty acid in the F group, being significant at 15 days of feeding. In the LCP-F group, 20:4n76 decreased slightly, with significant differences between this group and the HM-fed group at 15 days but not at 30 days of feeding. The concentration of 20:4n76 was significantly higher in LCP-F than in F group, at 15 and 30 days of feeding. The time course of 22:6n73 concentration in total plasma lipids was closer to that observed for 20:4n76 in the F group. However, 22:6n73 in the LCP group showed a pattern similar to that of HM fed infants, with significantly higher concentrations of this fatty acid than the F group from 15 days of feeding to the end of the study. The content of 20:5n73 remained stable throughout the study, with no significant differences between groups. Docosapentaenoic acid (22:5n73) was significantly higher in HM-fed infants than in formulafed infants. The percentages of 20:4n76 and 22:6n73 in plasma phospholipids, cholesterol esters and triglycerides are shown in Figure 1 . Infants fed the LCP-F showed higher percent of 20:4n76 at 30 days of feeding in all lipid fractions than infants fed F. The percent of 22:6n73 was also higher in phospholipids and triglycerides in LCP-F group and closer to that found in HM fed infants.
Data on PAC are shown in Table 4 . Throughout the study PAC did not differ significantly among the study groups, although HM-fed infants tended to have higher values than the formula fed groups.
Discussion
Several sources of LCP have been studied for supplementing infant formulas. These include fish oils (22:6n73), egg yolk phospholipids (20:4n76 þ Fig. 1 Arachidonic and docosahexaenoic acid levels (g/100g of total fatty acids) of plasma phospholipids, cholesterol esters and triglycerides in infants fed human milk (HM), formula (F) and LCP-supplemented formula (LCP-F). c: significantly different from HM. d: significantly different from F. 1: P40.05; 2: P50.01.
22:6n73), triglycerides from algae (22:6n73) or fungi (20:4n76). Fish provide 22:6n73 and variable amounts of 20:5n73 depending on the source (11) but typically greater than those found in human milk from mothers on a mixed diet (34) . Egg-yolk phospholipids contain variable ratios 22:6n73/20:4n76, depending on the hen's diet (37) . Oils from algae and fungi are enriched in one of the LCP series (n76 or n73) and thus, provide the advantage of adjusting the quantity of 20:4n76 and 22:6n73 in infant formulas separately. Otherwise, the ratio 20:4/22:6 would be determined by the composition of the LCP source instead of by the requirements of these fatty acids for infant development.
Phospholipids from pig brains are a purified blend containing LCP from the n76 and n73 series, and a high proportion of 20:4n76 and 22:6n73 with no 20:5n73. Combined with other fat blends currently used in infant formula manufacturing, a fatty acid pattern containing 20:4n76 and 22:6n73 could be achieved without detectable 20:5n73 levels (Table 1) . This LCP enriched-blend has been evaluated in newborn pigs. Feeding a LCP-supplemented formula for 17 days to newborn pigs produced significantly higher plasma phospholipids and liver microsomal 22:6n73 than feeding a control formula (31) without any adverse effect. Growth was similar between the study groups. Moreover, dietary LCP as pig brain phospholipids enhance the recovery of the damage small intestine after protein-energy malnutrition (32).
Carlson et al. found that preterm infants fed a formula supplemented with a high 22:6n73 and 20:5n73 fish oil had lower Z-score for weight by 40 weeks of postconcepcional age and at any other age in the first year of life than infants fed a conventional formula (17) . Correlation analyses suggested that this was related to a lower status of 20:4n76 in infants fed fish oil due to the high content of 20:5n73 in the supplemented formula (38) . In our study, plasma 20:4n76 content of infants fed LCP-F was higher than that of infants fed F (Table 4 ). In addition, 20:5n73 did not increase in LCP-F group because the experimental formula did not contain detectable amount of this fatty acid. Although this study was not specifically designed to assess growth, it is noteworthy that there were no differences on body weight, length and head circumference between groups for the first month of life (Table 3) . However, because of the small sample size, a type II error can not be discarded, therefore a larger study should be done to confirm no effects of the LCPsupplemented formula on growth. Nonetheless, other studies using both n73 and n76 supplemented formulas did not report any differences in growth between preterm infants fed the unsupplemented or supplemented formula either (20, 21, 22) .
This study shows the influence of human milk feeding on plasma saturated fatty acid composition. Infants fed human milk had higher concentration of 12:0, 14:0, 16:0 and 18:0 in total plasma lipids. This fact may be explained by several mechanisms. Firstly, the higher content of 12:0, 14:0 and 16:0 in the banked human milk than in formulas (Table 2 ) may explain the higher concentration of these fatty acid but not 18:0, which was found in similar percentages in human milk and in formulas. Another mechanism would be the better absorption of lipids from human milk due to the presence of bile salt-stimulated lipase (39) and to the distribution of fatty acids in the triacylglycerol molecule (40) . However in the present study, bile salt-stimulated lipase was inactivated because milk was pasteurised to avoid bacterial contamination. Finally, in human milk fatty acids shorter than 16:0 are primarily 12:0 and 14:0 in contrast to primarily 8:0 and 10:0 in formulas (34) . The different metabolic pathways of these fatty acids may influence the content of other saturated fatty acids in plasma. In fact, a study done in piglets showed that a diet containing 12:0 and 14:0 lead to a higher percentage of longer saturated fatty acids than a diet containing 8:0 and 10:0 as a medium chain fatty acids (41) .
Another interesting result is the lower and higher concentration of 18:1n79 and 18:2n76, respectively, found in plasma lipids of infant fed human milk. This fact can be due to the composition of human milk from Brazilian mothers, which have a lower content of 18:1n79 and a higher content of 18:2n76 than the formulas (Table 1) . Study formulas were adjusted to contain a fatty acid composition resembling that of the Spanish human milk from our geographical area (34) .
Feeding low birth weight infants a conventional formula with balanced levels of essential fatty acids but without LCP lead to a decrease on LCP plasma lipid contents in this study and in other previous studies (4). These results suggest that in formula fed infants desaturase activity and/or LCP synthesis alone cannot match plasma fatty acid levels of infants fed HM which provide preformed LCP. Recent studies have shown that preterm infants are able to synthesise LCP from precursors, even during the first weeks of life (42, 43) . Whether this activity can meet the requirement of growing tissues, especially those of central nervous system, is not known. The dietary level of a-linolenic acid, the precursor of 22:6n73, appears to be relevant (44). Our experimental diet containing LCP from n76 and n73 series resulted in a LCP fatty acid profile similar to that of human milk infants. The content of 20:4n76 in plasma lipids in the LCP-supplemented group were still lower than in human milk fed infants due to the lower content of this fatty acid in the formula compared to the banked human milk (0.34 vs 0.97%, on average). However, 22:6n73 in the LCPsupplemented group was closer to the human milk-fed group.
LCP addition to current infant formulas increases the antioxidant requirements of the formula and also in the infants, especially those born preterm. In particular, the vitamin E status of infants in certain studies has been decreased when LCP were added to formulas (25) . In our study, PAC have been determined as the ability of plasma to inhibit the oxidation of a highly-susceptiblesubstrate. By this method, the antioxidant properties of several substances in plasma (vitamins C and E, uric acid, antioxidant enzymes, etc.) can be measured as a pool. Our results agree with those of other studies using n73 LCP-formulas (24, 26) : no significant differences were found between infants fed the LCP supplemented or unsupplemented formula likely due to the proper stabilisation of the brain PL and/or the formula containing them. Infants fed human milk tended to have a higher PAC, and also a higher variability between samples. Those results may be explained by the presence of some antioxidant components in human milk (45) . However, it should be pointed that our method has not been validated in infants, and hence the biological significance of these data remains to be clarified.
The main goal of this study was to evaluate a phospholipid source of LCP in a formula for feeding preterm infants. This formula increased the amount of 22:6n73 in plasma to levels similar to those in human milk fed infants, and avoided the decline of 20:4n76 that occurs when 22:6n73 without 20:4n76 is fed. There was no evidence of peroxidation in infants fed the LCP-F because total plasma antioxidant capacity was not impaired in comparison to infants fed a standard formula. Additional and larger studies including visual and cognitive evaluations should be done to prove the efficacy of this LCP source.
